David E. Gerber · researcher · YYNN

David E. Gerber

? TBD

researcher

Ratings
0

Nobody has rated this yet. Be the first!

Works
2

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

scientific article published on 2 December 2016

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

scientific article (publication date: 22 October 2015)

Lists
0

Instance of

Occupation

Wikidata